ImmunityBio (IBRX) Non-Current Deferred Tax Liability (2015 - 2022)

ImmunityBio (IBRX) has 7 years of Non-Current Deferred Tax Liability data on file, last reported at $162000.0 in Q2 2022.

• Non-Current Deferred Tax Liability for Q2 2022 came in at $162000.0, down 4.71% year-over-year; the trailing twelve-month figure through Jun 2022 was $162000.0 (down 4.71% YoY), and the FY2021 annual result was $162000.0, down 96.65% from the prior year.
• Non-Current Deferred Tax Liability steadied at $162000.0 in Q2 2022 per IBRX's latest filing, from $162000.0 in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $4.8 million in Q4 2020 and troughed at $122000.0 in Q3 2018.
• A 4-year average of $658000.0 and a median of $170000.0 in 2021 frame the typical range for Non-Current Deferred Tax Liability.
• The sharpest annual moves came in 2021 and 2022: Non-Current Deferred Tax Liability tumbled 96.65% in 2021, then retreated 4.71% in 2022.
• A 4-year view of Non-Current Deferred Tax Liability shows it stood at $122000.0 in 2018, then surged by 3865.57% to $4.8 million in 2020, then plunged by 96.65% to $162000.0 in 2021, then changed by 0.0% to $162000.0 in 2022.
• Business Quant data shows IBRX's Non-Current Deferred Tax Liability at $162000.0 in Q2 2022, $162000.0 in Q1 2022, and $162000.0 in Q4 2021.